Moreover, we observed that positive expression of HDAC1 was associated with the downregulation of OAZ1 in NSCLC patients with platinum-based treatment, and predicted drug resistance and poor prognosis. This evidence concerns the gene HDAC1 and non-small cell lung carcinoma.